Treatment of Guillain-Barré Syndrome

First-Line Immunotherapy Options

The American College of Cardiology is not applicable here, however, IVIg at 0.4 g/kg daily for 5 days is the first-line treatment for GBS and should be initiated as early as possible in patients with significant disability (GBS disability score ≥3) 1
Both IVIg and plasma exchange (PE) are equally effective treatments for GBS, but IVIg is generally preferred as first-line therapy due to easier administration, wider availability, higher completion rates, and fewer adverse effects compared to PE 2, 3, 1

The dose for IVIg is 0.4 g/kg body weight daily for 5 consecutive days 1, 4
The timing for IVIg is most effective when started within 2 weeks of symptom onset 2, 3
The dose for PE is 200-250 ml/kg total plasma volume, typically divided into 5 sessions over 2 weeks 2, 3
The cost consideration for PE is less expensive than IVIg (~$4,500-5,000 vs $12,000-16,000), which may be relevant in resource-limited settings 5, 2

The "20/30/40 Rule" for respiratory assessment indicates a patient is at high risk for respiratory failure requiring mechanical ventilation if vital capacity <20 ml/kg, maximum inspiratory pressure <30 cmH₂O, or maximum expiratory pressure <40 cmH₂O 1, 4
Approximately 20% of GBS patients will require mechanical ventilation 4

The following medications can worsen neuromuscular function and must be avoided: β-blockers, aminoglycosides 1, 4, 6

40% of patients do not improve in the first 4 weeks following treatment—this does NOT necessarily indicate treatment failure 1, 4
Recovery can continue for more than 5 years after disease onset 4, 6
Treatment-related fluctuations (TRFs) occur in 6-10% of patients within 2 months of initial improvement 1, 4

Pain management is common in GBS and requires aggressive treatment with neuropathic pain medications 4, 6
DVT prophylaxis is essential due to immobility 1, 6
Prevention of pressure ulcers through regular repositioning 1, 6
Prevention of hospital-acquired infections (pneumonia, UTIs) 4, 6

In children, IVIg is strongly preferred over PE (0.4 g/kg daily for 5 days) 6
In resource-limited settings, small volume plasma exchange (SVPE) is a novel, low-cost option (~$500) that has shown safety and feasibility in India and Bangladesh, but requires large-scale studies before routine implementation 5, 3

80% of patients regain walking ability at 6 months after disease onset 1, 4
Mortality is 3-10%, most commonly from cardiovascular and respiratory complications 1, 4
Risk factors for mortality include advanced age, severe disease at onset, and lack of ICU support when needed 5, 1
Recurrence is rare (2-5%) but higher than general population lifetime risk (0.1%) 4
Long-term residual complaints include neuropathic pain, weakness, and fatigue 4, 6

All patients with Guillain-Barré syndrome should be admitted to an inpatient unit with rapid transfer capability to ICU, according to the Journal of Clinical Oncology 7

The Journal of Clinical Oncology recommends avoiding certain medications, including β-blockers, IV magnesium, fluoroquinolones, and macrolide antibiotics, as they can worsen neuromuscular function 7

The Journal of Clinical Oncology suggests using non-opioid neuropathic pain medications, such as gabapentin, pregabalin, or duloxetine, for pain management 7
Nature Reviews Neurology reports that severe pain occurs in at least one-third of patients at 1 year and can persist for >10 years 8

According to Nature Reviews Neurology, 80% of patients regain walking ability at 6 months after disease onset, and mortality is 3-10%, most commonly from cardiovascular and respiratory complications 8
The modified Erasmus GBS Outcome Score (mEGOS) can be used to predict walking ability at 6 months, as recommended by Nature Reviews Neurology 8

Nature Reviews Neurology suggests arranging rehabilitation with a specialist, physiotherapist, and occupational therapist before discharge, and using exercise programs to improve physical fitness and independence 8